Comprehensive Digestive Stool Analysis 2.0 (CDSA 2.0)

Comprehensive Stool Analysis for Optimal Clinical Utility

Proceed to Clinical Overview

The Comprehensive Digestive Stool Analysis 2.0™ (CDSA 2.0) offers unique insight into overall and gastrointestinal health by assessing a combination of novel stool biomarkers.

This stool analysis evaluates:

  • Digestion/Absorption Markers
  • Immunology (Inflammation) Markers

    • Pancreatic Elastase 1 (PE1), a biomarker of exocrine pancreatic function Immunology (Inflammation) Markers
    • Calprotectin, an FDA-cleared biomarker that effectively differentiates between Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD)

  • Gut Metabolic Markers
  • Gut Microbiology Markers
  • Gold standard O&P (ova & parasite) technology as well as EIA (Enzyme Immunoassay) for identification of common parasites

This diagnostic stool analysis provides immediate, actionable clinical information for the estimated 50% of patients seen by primary care practitioners who have gastrointestinal complaints. For greater insight into the clinical utility of the CDSA 2.0, please read the Clinical Overview below.

CDSA 2.0 Stool Analysis Offers Insight into Common Gastrointestinal Conditions

Evidence suggests that both local and systemic health issues may begin as imbalances in gastrointestinal function. Some of the consequences of imbalanced gastrointestinal health are:

  • Maldigestion
  • Malabsorption
  • Irritable Bowel Syndrome (IBS)
  • Altered GI immune function
  • Bacterial/fungal overgrowth
  • Chronic dysbiosis


Clinical Overview

What is the Comprehensive Digestive Stool Analysis™ (CDSA 2.0)?

The Comprehensive Digestive Stool Analysis 2.0™ (CDSA 2.0) provides unique insight into overall and gastrointestinal health by assessing a combination of novel stool biomarkers. The CDSA 2.0 provides an informative and flexible screening of gastrointestinal function providing information on:

  • Digestion/Absorption:
    • Pancreatic Elastase 1
    • Putrefactive Short–Chain Fatty Acids
    • Additional biomarkers available
      • Chymotrypsin
      • Fecal Fats
  • Inflammation/Immunology:
    • Eosinophil Protein X (EPX)
    • Calprotectin
  • Gut Metabolic Markers
    • Beneficial Short–Chain Fatty Acids (SCFA) with n–Butyrate
    • pH
    • Beta–Glucuronidase
    • Secondary Bile Acids
      • Lithocholic acid (LCA)
      • Deoxycholic acid (DCA)
      • LCA/DCA Ratio
  • Gut Microbiology Markers
    • Beneficial Bacteria
    • Additional Bacteria
    • Mycology
    • Parasitology Microscopic
    • Parasitology EIA
      • Cryptosporidium
      • Giardia lamblia
      • Entamoeba histolyti

When Should the CDSA 2.0 be considered?

CDSA 2.0 can reveal important clinical information about many common symptoms such as gas, bloating, abdominal pain, diarrhea, and constipation. This stool analysis also provides assessment for a differential diagnosis between inflammatory bowel disease and irritable bowel syndrome, plus a reliable assessment of exocrine pancreatic function. In addition, patients with risk factors for parasite acquisition can be evaluated with the CDSA 2.0.

What advantage does the CDSA 2.0 offer compared to other diagnostics?

Traditional GI testing has required advanced imaging and inconvenient testing procedures that can be costly. The CDSA 2.0 stool analysis offers a user-friendly way to provide clinicians with valuable insight into GI imbalances

What can clinicians and patients expect from the CDSA 2.0 offer compared to other diagnostics?

Evidence suggests that both local and systemic health issues may begin as imbalances in Gastrointestinal function. The CDSA 2.0 stool test provides immediate, actionable clinical information for patients presenting with GI complaints. It aids clinicians in the identification of root cause(s) of digestive discomfort and supports identification of targeted treatments.

Test Type: Stool Analysis

Analyte List
Bacteriology Culture, aerobic
Bacteriology Culture, aerobic x 3
Bacteriology Culture, anaerobic
Beneficial SCFAs
Beta-Glucuronidase
Bile Acids
Calprotectin
Cryptosporidium EIA
Deoxycholic Acid
Entamoeba histolytica
Eosinophil Protein X (EPX)
Giardia lamblia EIA
LithoCholic Acid
Pancreatic Elastase
Parasite Identification, Concentrate Prep
Parasite Identification, Trichrome Stain
Putrefactive SCFAs
Yeast Culture
n-Butyrate %
pH
CPT Codes  
Bacteriology Culture, aerobic 87045
Bacteriology Culture, aerobic x 3 87046
Bacteriology Culture, anaerobic 87075
Beneficial SCFAs 82492
Beta-Glucuronidase 84311
Bile Acids 82239
Calprotectin 83993
Cryptosporidium EIA 87328
Entamoeba histolytica 87336
Eosinophil Protein X (EPX) 83520
Giardia lamblia EIA 87329
Pancreatic Elastase 82656
Parasite Identification, Concentrate Prep 87177
Parasite Identification, Trichrome Stain 87209
Yeast Culture 87102
pH 83986
Specimen Requirements
5cc stool in each vial - 3 SAF, 1 Cary Blair, 1 Formalin; 40ml stool in white-top cup. May be random stool or purge.